Today: 27 April 2026
Browse Category

Stock Market 10 February 2026

AI stocks today: Cisco’s new chip enters the race as Nvidia faces China guardrails

AI stocks today: Cisco’s new chip enters the race as Nvidia faces China guardrails

Cisco unveiled its Silicon One G300 chip and router for AI data centers, aiming to boost network efficiency and compete with Nvidia and Broadcom. Nvidia, Broadcom, and AMD shares fell amid renewed U.S. licensing scrutiny on China and concerns over AI capital spending. Cisco stock edged up 0.3%. Investors are watching U.S. payroll and inflation data for signals on interest rates.
10 February 2026
··········
Datadog stock jumps 15% after earnings beat, with AI selloff still in the background

Datadog stock jumps 15% after earnings beat, with AI selloff still in the background

Datadog shares jumped nearly 15% to $130.86 after the company beat Wall Street’s fourth-quarter estimates, reporting $953.2 million in revenue and 59 cents adjusted profit per share. The S&P 500 software index rose 1.3%. Datadog forecast full-year revenue of up to $4.10 billion and ended 2025 with $4.47 billion in cash. U.S. retail sales were flat in December as Treasury yields fell.
10 February 2026
····
Qualcomm stock today: QCOM edges higher as Morgan Stanley warns memory crunch could bite again

Qualcomm stock today: QCOM edges higher as Morgan Stanley warns memory crunch could bite again

Qualcomm shares rose 0.5% to $139.61 Tuesday after a turbulent week marked by supply concerns. Morgan Stanley resumed coverage with an underweight rating and a $132 target, citing memory shortages and weak handset demand. A company executive sold 3,200 shares under a preset 10b5-1 plan. Qualcomm recently forecast revenue and profit below estimates, blaming a global memory chip shortage.
10 February 2026
···
Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific shares rose 0.7% to $74.61 by early afternoon Tuesday after a 2.8% drop Monday. New four-year Farapulse data showed higher treatment success than thermal ablation, with no long-term safety issues. Around 9.1 million shares traded by 1:15 p.m. The next major update is expected from the CHAMPION-AF trial results at ACC.26 on March 28.
10 February 2026
··
Intuit stock price slips today after analyst target cuts; Mailchimp ecommerce push in focus

Intuit stock price slips today after analyst target cuts; Mailchimp ecommerce push in focus

Intuit shares fell 0.7% to $434.58 Tuesday, trading between $429.22 and $450.99 as BMO and TD Cowen cut price targets but kept positive ratings. Analysts cited tax-season trends and AI risks. Investors are watching Mailchimp’s new ecommerce tools and upcoming quarterly results for signs of demand. Thirty-day implied volatility in software stocks stayed elevated.
10 February 2026
·
Citi stock drops as banks lag on softer U.S. data — what to watch next

Citi stock drops as banks lag on softer U.S. data — what to watch next

Citigroup shares fell 2.3% to $120.90 in early afternoon trading Tuesday, near session lows, after weak U.S. retail sales data pushed Treasury yields lower and pressured bank stocks. JPMorgan, Bank of America, and Wells Fargo also declined. Investors await Citi’s Feb. 11 conference remarks and key U.S. economic data for signals on rates and profit outlooks.
10 February 2026
····
PepsiCo stock price slips as Coca-Cola revenue miss and weak retail sales keep demand worries alive

PepsiCo stock price slips as Coca-Cola revenue miss and weak retail sales keep demand worries alive

PepsiCo shares slipped 0.3% to $165.90 Tuesday after U.S. retail sales data showed flat December spending and “core” sales dipped 0.1%. The company plans to cut snack prices by up to 15% and will address strategy at the Feb. 18 CAGNY conference. Coca-Cola shares fell 1.8% after missing revenue forecasts and warning on 2026 growth.
10 February 2026
···
Bloom Energy stock turns choppy as SEC filing details Oracle warrant and Brookfield AI financing

Bloom Energy stock turns choppy as SEC filing details Oracle warrant and Brookfield AI financing

Bloom Energy shares fell 0.8% to $153.99 in midday trading Tuesday after disclosing a Brookfield-backed $5 billion financing framework and a potential Oracle warrant for up to 3.53 million shares at $113.28. The company’s annual filing showed 2025 revenue up 37% to $2.02 billion, with a net loss despite positive operating income.
10 February 2026
·······
Kenvue stock pops today: what KVUE investors are watching into earnings and the Kimberly-Clark deal

Kenvue stock pops today: what KVUE investors are watching into earnings and the Kimberly-Clark deal

Kenvue shares rose 1.8% to $18.50 Tuesday, tracking gains in Kimberly-Clark after shareholders approved a cash-and-stock takeover valuing Kenvue at about $19.10 per share. Kenvue’s dividend record date is Feb. 11, with quarterly results due Feb. 17. The deal is expected to close in the second half of 2026, pending regulatory approval.
10 February 2026
···
CyberArk stock hovers near $410 as Nasdaq flags Feb. 10 halt ahead of Palo Alto merger close

CyberArk stock hovers near $410 as Nasdaq flags Feb. 10 halt ahead of Palo Alto merger close

CyberArk shares rose 0.3% to $410.32 midday Tuesday after Nasdaq said trading will halt after hours as Palo Alto Networks moves to close its takeover. The deal, set to close before markets open Feb. 11, offers CyberArk holders $45 in cash and 2.2005 Palo Alto shares per share. The implied value stood near $412, with a $1.75 spread. Palo Alto shares also edged higher.
10 February 2026
···
Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck shares fell 0.5% to $117.01 after SEC filings showed insider stock sales by two executives on Feb. 9. Chief Marketing Officer Chirfi Guindo sold 10,000 shares; Executive Vice President Jennifer Zachary exercised and sold 121,573 shares. The moves followed a revenue forecast below Wall Street estimates. Merck underperformed the broader market and sector peers.
10 February 2026
··
1 … 155 156 157 158 159 … 1,393

Stock Market Today

  • Options Traders Reflect on Toughest Lessons Learned
    April 27, 2026, 3:59 PM EDT. Options traders discuss valuable insights gained from difficult experiences in the derivatives market. Trading options-contracts granting the right to buy or sell an asset at a set price-requires understanding complex risks. Many traders highlight the importance of discipline, managing losses, and resisting emotional decisions. These lessons often come after costly mistakes, underlining how quickly volatility and leverage can amplify losses. Industry voices stress education and strategy adjustments as key to survival and success in options trading.

Latest article

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

27 April 2026
Intellia Therapeutics reported its CRISPR drug lonvo-z cut hereditary angioedema attacks by 87% versus placebo in a late-stage trial, with 62% of treated patients attack- and therapy-free over six months. The company has started a rolling U.S. approval application. No serious adverse events were reported. Intellia shares fell 0.9% to $13.51 after initial gains.
U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

27 April 2026
U.S. Energy Corp. signed a five-year helium sales deal with an unnamed global industrial gas company, securing a buyer for output from its planned Big Sky Carbon Hub in Montana. The contract covers up to 1.2 million cubic feet a month at a fixed $285 per thousand cubic feet, with inflation adjustments starting March 2028. U.S. Energy shares rose 20.8% to $1.12 on heavy volume. The agreement is “take-or-pay,” with the buyer handling pickup at the plant.
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

27 April 2026
Veradermics shares rose 40% Monday after its oral hair-loss drug VDPHL01 met all main goals in a Phase 2/3 trial of 519 men. Patients taking the drug saw average hair count increases of 30.3 to 33.0 hairs per square centimeter over six months, compared to 7.3 for placebo. No treatment-related serious or heart-related adverse events were reported.
Go toTop